Investigational drug · Phase 3
NBP608
Also called: Mid Potency, Potency
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Varicella (Chickenpox).
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "NBP608"
First trial start
2026
Jul 4, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NBP608", any sponsor or status.
Conditions studied
As listed on its trial records.
- Varicella (Chickenpox)
Largest trials
Live from ClinicalTrials.gov: studies naming "NBP608" as an intervention, largest first.
- Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and OverPivotal-lookingCompleted
SK Chemicals Co., Ltd.Industry
NCT03120364 · 824 participants · Start Sep 9, 2015 · Primary completion Dec 16, 2015
Drug: NBP608; Zostavax · For: Herpes Zoster
Sites: Seoul, South Korea
- SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 YearsPivotal-lookingRecruiting
SK Bioscience Co., Ltd.Industry
NCT07415252 · 780 participants (planned) · Start Jul 4, 2026 · Primary completion Feb 13, 2027
Drug: NBP608 (Mid Potency); NBP608 (Low Potency) and 2 more · For: Varicella (Chickenpox)
Sites: San Pedro Sula, Honduras; Tegucigalpa, Honduras; Manila, Philippines · 14 sites in all
- Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and OverPivotal-lookingCompleted
SK Chemicals Co., Ltd.Industry
NCT03116594 · 675 participants · Start Jan 3, 2014 · Primary completion Apr 8, 2014
Drug: NBP608; Zostavax · For: Herpes Zoster
Sites: Seoul, South Korea
- Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of AgePivotal-lookingCompleted
SK Bioscience Co., Ltd.Industry
NCT03114943 · 516 participants · Start Jul 14, 2016 · Primary completion Jun 28, 2017
Drug: NBP608; Varivax · For: Varicella
Sites: Dasmariñas, Philippines
- The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of AgePivotal-lookingCompleted
SK Chemicals Co., Ltd.Industry
NCT03114982 · 152 participants · Start May 2016 · Primary completion Jul 2016
Drug: NBP608; Varivax · For: Varicella
Sites: Muntinlupa City, Philippines
SK Chemicals Co., Ltd.Industry
NCT03121638 · 150 participants · Start Nov 2012 · Primary completion Feb 2013
Drug: VARIVAX; ZOSTAVAX and 3 more · For: Varicella Zoster; Immunization; Infection
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Chemically tailored lipids mediate solid-phase RNA programming of mineralized microenvironments.
Liu J, Chen Q, Thussananutiyakul J, et al. · Biomaterials 2027
- In situ bioactive nanocoating enables transocular delivery of permeable drug for dual-location intervention of ocular surface and fundus disorders.
Wang Z, Lv W, Su Y, et al. · Bioact Mater 2027
- Targeted degradation of VEGFR2 via PROTAC encapsulated by cRGD-liposome reverses pathological corneal neovascularization.
Feng K, Wei M, Guan W, et al. · Biomaterials 2027
- Gentianae Macrophyllae Radix inhibits renal fibrosis in type 2 diabetes via regulating aldose reductase.
Xu Z, Zhang Y, Wang Q, et al. · J Ethnopharmacol 2027
- Plumieride ameliorates type 2 diabetes and colitis by regulating intestinal functions.
Zheng T, Gao X, Miao Y, et al. · J Ethnopharmacol 2027
- Iron-quercetin-incorporated PCL/PEO nanofibrous scaffolds for ADSC secretome modulation and in vitro regenerative responses.
Daranarong D, Kantapan J, Jenvoraphot T, et al. · Biomater Adv 2027
Also in development for Varicella (Chickenpox)
- MG1111BARICELA, Barycela inj.Phase 32 trials
Green Cross Corporation · Varicella, Varicella (Chickenpox), Chickenpox Vaccine
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.